Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

BACKGROUND AND AIMS: Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficacy of ontamalimab in TURANDOT II. METHODS: TURANDO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Crohns Colitis
Main Authors: Reinisch, Walter, Sandborn, William J, Danese, Silvio, Hébuterne, Xavier, Kłopocka, Maria, Tarabar, Dino, Vaňásek, Tomáš, Greguš, Miloš, Hellstern, Paul A, Kim, Joo Sung, Sparrow, Miles P, Gorelick, Kenneth J, Hoy, Michael, Goetsch, Martina, Bliss, Caleb, Gupta, Charu, Cataldi, Fabio, Vermeire, Séverine
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8218706/
https://ncbi.nlm.nih.gov/pubmed/33599720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjab023
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados